Matthew J. Frigault, MD, is the inaugural incumbent of the John and Ashley Ranelli Endowed Scholar in Cancer Innovation at Massachusetts General Hospital. As the clinical director of Mass General Cancer Center’s Cellular Immunotherapy Program, Dr. Frigault’s clinical and research excellence have helped establish Mass General’s Cellular Immunotherapy Program as a national referral center for both standard-of-care and investigational cellular therapies. He also serves as a medical oncologist in the Hematologic Malignancy Program and is an assistant professor of medicine at Harvard Medical School.

Since joining Mass General in 2017, Dr. Frigault has established himself as a leader in the clinical management, development and translational research of immune effector cell (IEC) therapies, including chimeric antigen receptor (CAR) T-cell therapies. His work focuses on improving the safety and efficacy of cellular therapies and has resulted in numerous first-in-human trials and papers that have shaped clinical guidelines and expanded access to CAR T-cell therapies for high-risk populations. Dr. Frigault was a key contributor to the Cellular Immunotherapy Program’s INCIPIENT trial, which showed the first promising results of CAR T-cell therapy for patients with recurrent glioblastoma. His research has been widely recognized at national and international conferences, and he has authored over 75 peer-reviewed publications with significant contributions to IEC clinical practices.

Dr. Frigault is also a dedicated teacher and educator. He trains medical students, residents, fellows and junior faculty in leading-edge cellular therapy management and translational research, and his mentorship has inspired the next generation of clinician-scientists in the rapidly evolving field of cell and gene therapy. After graduating magna cum laude from the College of the Holy Cross in Worcester, Mass., Dr. Frigault earned his medical degree at the University of Pennsylvania and completed his postdoctoral training at The Johns Hopkins Hospital and Mass General Cancer Center.